St. Jude eyes larger patient group in new renal denervation study

St. Jude Medical's Enlighn renal denervation system

Medtech giant St. Jude Medical (NYSE:STJ) launched a new trial of its Enlightn renal denervation system, hoping to demonstrate the value of the technology in a larger clutch of patients.

Prior studies have generally focused on patients with "drug-resistant" hypertension, those with a systolic blood pressure reading above 160 mmHg despite treatment with 3 or more drugs. The new Enlightn II post-market study is eying the "uncontrolled" population, patients with a less severe form of hypertension.

The new trial builds on the success of Enlightn I, in which researchers concluded that treatment with St. Jude’s renal denervation system produced significant and sustained reduction in systolic blood pressure. Patients on average experienced a stable 26 mmHg reduction in blood pressure 6 months after treatment, according to a press release.

"There is convincing evidence from studies like the Enlightn I trial linking renal denervation to improved blood pressure in patients who have drug-resistant hypertension," principal investigator Dr. Johannes Brachmann said in prepared remarks. "Expanding this research to patients with less severe forms of hypertension is important as this minimally invasive approach allows for a shorter procedure time and a potentially faster recovery time, which may benefit more patients with uncontrolled hypertension."

Enlightn II will ultimately enroll about 500 patients at 40 sites in Europe and Australia.

Some tough competition

St. Jude faces some stiff competition in the renal denervation market, where Medtronic’s (NYSE:MDT) Symplicity system, gained through the January 2011 acquisition of Ardian, already has a head start. Medtronic is also the closest to winning FDA approval for renal denervation, with U.S. clinical trials approved in the summer of 2011.

In May 2012 St. Jude landed CE Mark approval and announced commercial launch for its Enlightn renal denervation system as a treatment for hypertension. St. Jude last year touted study results finding that its Enlightn renal denervation system lowered high blood pressure faster than Medtronic’s Symplicity.

Fellow medtech giant Boston Scientific’s (NYSE:BSX) also looking to stay apace in the highly competitive renal denervation market, expecting CE Mark approval and European commercial launch for its RDN system sometime this year. Boston Scientific expects to begin U.S. clinical trials in 2014.

Massachusetts device maker Covidien (NYSE:COV) earlier this month announced global commercial launch of its OneShot renal denervation system, which Covidien gained through the April 2012 acquisition of Maya Medical in a deal worth up to $230 million,. The company plans over the next few months to roll out the device in markets in Europe, the Middle East, Africa, Asia and Latin America.

No renal denervation system has yet been cleared for the U.S. market.

RSS From Medical Design & Outsourcing

  • Vicon captures a new development in motion capture (mocap)
    Vicon announced the launch of its new flagship camera platform, the Vicon Vantage. Drawing on over 30 years’ of motion capture (mocap) experience, the Vantage platform combines innovative technology with accessible design to open up motion capture to a broader audience. Vicon is a motion capture technology specialist company for science and life industries. Advances in […]
  • Satel’s latest product sets a new milestone in radio manufacturing
    The new Satelline TR4, from the Finnish manufacturer of radio data transmission systems, Satel sets a new milestone. The compact UHF transceiver with transmitting power of 1,000 mW is compatible with the protocols of Pacific Crest, Trimble and Satel. The type certifications in all important regions of the world make the TR4 ideal for integration […]
  • SCHURTER announces retirement of founder and management changes
    SCHURTER announced the retirement of founder Bruno H. Schurter on June 29, 2015. The company, founded in 1982 in Petaluma, California, will change management effective July 1, 2015. Bruno H. Schurter, president and CEO will retire after 33 years of heading up the privately held company, which is a subsidiary of SCHURTER Holding AG, founded in […]
  • Silicone: Expanding the horizon for modern medical devices
    Editor’s note: This article comes from Albright Technologies a manufacturer of custom silicone prototypes and provides volume production for medical, pharmaceutical, industrial, and other applications. Silicone materials have been around for more than 70 years. Beginning in the 1960s, silicones have played an important and evolving part in products designed for the medical field. Since that time, […]
  • DeNovo Sciences appoints a molecular diagnostics veteran as new CSO
    DeNovo Sciences, a producer of  liquid biopsy products, announced the appointment of Dr. Yixin Wang as Chief Scientific Officer (CSO). Dr. Wang is a veteran in molecular diagnostics where he has played significant R&D roles at large, multi-national companies including Parke-Davis/Pfizer, Veridex/Johnson & Johnson and Ventana/Roche. He will lead strategic initiatives for clinical development of DeNovo’s […]
  • Albright Technologies expands their silicone offerings
    Albright Technologies, a rapid silicone prototyper, has added silicone injection molding tooling and services to its product lineup. Liquid silicone injection molding became a suitable product offering as Albright expanded its offerings to better serve the silicone molding market. While silicone prototypes are commonly manufactured with low volumes in mind; injection molded liquid silicone rubber parts are […]
  • Applied Silver launches SilvaClean, silver treatment for textiles
    Applied Silver, Inc, is launching SilvaClean, a state-of-the-art silver treatment for textiles, at the Association for Professionals in Infection Control and Epidemiology’s (APIC) forty-second Annual Conference taking place at the Music City Center in Nashville, from June 27 through June 29. Hospitals have invested significantly in reducing the potential of infection through products and processes designed […]
  • Two-Component technology for improved quality of life
    In the field of injection molding and mold making, toolcraft covers all processes within the added value chain–from the design and selection of materials through to the creation of finished and qualified products. Complete solutions offered include injection molding for parts in the small and extremely small component areas, e.g. for medical technology. Utilizing two-component […]
  • GDS security protects medical devices from hackers
    As data breaches become more commonplace with serious consequences to personal, corporate and national security, it is clear that there is no shortage of accomplished and effective hackers ready to steal data and trade it on the open market. Global Data Sentinel (GDS) has the ability to provide retroactive security to remove access to email […]
  • BRAEBON and SomnoMed combine products to combat sleep apnea
    BRAEBON Medical Corporation announces that the DentiTrac oral appliance compliance system has passed a regulatory hurdle and is now FDA cleared in the USA for use with the SomnoDent oral device. BRAEBON congratulates SomnoMed for being the first company to achieve this milestone. “We are pleased DentiTrac is launching in the US market. Accurate oral appliance […]
  • For advanced shielded plastic connector solution, ODU delivers with latest product
    ODU, a company which designs and manufactures connector solutions and cable assemblies, is announcing ODU MEDI-SNAP EMC, the advanced shielded plastic connector solutions, to the US market. ODU MEDI-SNAP EMC is the latest addition to ODU’s Push-Pull circular connectors. The advanced medical connector solution is lightweight, autoclavable, sterilizable and it offers a touch proofed housing and reliable […]

Leave a Reply